PROLONGED SURVIVAL IN HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) PATIENTS (PTS) WITH-7/DEL(7Q) TREATED WITH AZACITIDINE (AZA)

被引：0
|
作者：
Mufti, G. J. [1 ]
Garcia-Manero, G. [2 ]
Hovarth, N. [3 ]
Lim, Z. [4 ]
Quesnel, B. [5 ]
Leone, G. [6 ]
Bennett, J. [7 ]
Sanz, G. [8 ]
McKenzie, D. [9 ]
Backstrom, J. [9 ]
Beach, C. L. [9 ]
机构：
[1] Kings Coll Hosp London, London, England
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] IMVS, Adelaide, SA, Australia
[4] Kings Coll London, London WC2R 2LS, England
[5] CHU Lille, Serv Malad Sang, F-59037 Lille, France
[6] Policlin Gemelli, Div Ematol, Rome, Italy
[7] Univ Rochester, Rochester, NY 14627 USA
[8] Hosp Univ La Fe, Inst Name, Valencia, Spain
[9] Pharm Corp, Overland Pk, KS USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0928
引用
收藏
页码：369 / 370
页数：2
相关论文
共 50 条
  • [41] Long-Term Outcome Of Higher-Risk MDS Patients Treated With Azacitidine: Single Centre Experience
    Ricco, Alessandra
    Sgherza, Nicola
    Rossi, Antonella Russo
    Carluccio, Paola
    Franco, Adele
    Pasciolla, Crescenza
    Casieri, Paola
    Specchia, Giorgina
    BLOOD, 2013, 122 (21)
  • [42] Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
    Fenaux, Pierre
    Gattermann, Norbert
    Seymour, John F.
    Hellstroem-Lindberg, Eva
    Mufti, Ghulam J.
    Duehrsen, Ulrich
    Gore, Steven D.
    Ramos, Fernando
    Beyne-Rauzy, Odile
    List, Alan
    McKenzie, David
    Backstrom, Jay
    Beach, Charles L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 (02) : 244 - 249
  • [43] Predicting the outcome of patients with higher-risk myelodysplastic syndrome treated with hypomethylating agents
    Itzykson, Raphael
    Fenaux, Pierre
    LEUKEMIA & LYMPHOMA, 2012, 53 (05) : 760 - 762
  • [44] Monosomal karyotype is an independent predictor of survival in patients with higher-risk myelodysplastic syndrome
    Xing, Ruixian
    Li, Chengwen
    Gale, Robert Peter
    Zhang, Yue
    Xu, Zefeng
    Qin, Tiejun
    Li, Bing
    Fang, Liwei
    Zhang, Hongli
    Pan, Lijuan
    Hu, Naibo
    Qu, Shiqiang
    Xiao, Zhijian
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (10) : E163 - E168
  • [45] A randomized study of two dose levels of intravenous (IV) clofarabibe (CLO) in the treatment of patients (pts) with higher-risk myelodysplastic syndrome (MDS)
    Jabbour, E.
    Kantarjian, H.
    Garcia-Manero, G.
    Kashani, F. Ravandi
    Borthakur, G.
    Estrov, Z.
    Gandhi, V.
    Byrd, A.
    Kwari, M.
    Faderi, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] MODELLING THE LONG-TERM SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) DEL (5Q) TREATED WITH LENALIDOMIDE
    Benettaib, B.
    Lee, D.
    Dhanasiri, S.
    Brereton, N.
    HAEMATOLOGICA, 2013, 98 : 310 - 310
  • [47] Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    List, Alan F.
    Cuthbertson, David
    Paquette, Ronald
    Latham, Deborah
    Afable, Manual
    Paulic, Katarina
    Loughran, Thomas P., Jr.
    Maciejewski, Jaroslaw P.
    BLOOD, 2008, 112 (11) : 88 - 89
  • [48] Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS)
    Chen, James
    Johnson, Lisa
    McKenna, Kelly
    Choi, Timothy
    Duan, Jiaqi
    Feng, Dongdong
    Tsai, Jonathan
    Garcia-Martin, Natalia
    Sompalli, Kavitha
    Maute, Roy
    Vyas, Paresh
    Majeti, Ravindra
    Takimoto, Chris
    Liu, Jie
    Ramsingh, Giridharan
    Chao, Mark
    Volkmer, Jens-Peter
    Weissman, Irving
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S317 - S318
  • [49] Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome
    Chien, Kelly S.
    Kim, Kunhwa
    Nogueras-Gonzalez, Graciela M.
    Borthakur, Gautam
    Naqvi, Kiran
    Daver, Naval G.
    Montalban-Bravo, Guillermo
    Cortes, Jorge E.
    DiNardo, Courtney D.
    Jabbour, Elias
    Alvarado, Yesid
    Andreeff, Michael
    Bose, Prithviraj
    Jain, Nitin
    Kadia, Tapan M.
    Huang, Xuelin
    Sheppard, Kimberly B.
    Klingner-Winton, Cheri
    Pierce, Sherry A.
    Dong, Xiao Qin
    Soltysiak, Kelly A.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 195 (03) : 378 - 387
  • [50] Outcome of Patients with Lower-Risk Myelodysplastic Syndrome (MDS) After Azacitidine (AZA) Treatment Failure.
    Mishra, Asmita
    Lancet, Jeffrey E.
    Al Ali, Najla H.
    Padron, Eric
    Ho, Viet Q.
    Little, Bryan J.
    Pinilla-Ibarz, Javier
    List, Alan F.
    Komrokji, Rami S.
    BLOOD, 2012, 120 (21)
12345